Delcath Systems Inc
$16.25
$0.03 (+0.18%)
$16.12Day Range$16.50
Key Statistics
Market Cap
$562.81M
Shares Outstanding
34.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 19, 2000
Round Lot
100
Locale
US
Trading Data
Day Open
$16.47
Day High
$16.50
Day Low
$16.12
Volume
437.2K
VWAP
$16.28
Prev Close
$16.22
Transactions
--
Acc. Volume
--
About Delcath Systems Inc
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
SURGICAL & MEDICAL INSTRUMENTS & APPARATUSSIC 3841156 employees566 QUEENSBURY AVENUE, QUEENSBURY, NY, 12804(518) 743-8892IPO Oct 19, 2000US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000872912
- Composite FIGI
- BBG000BY2VF5
- Share Class FIGI
- BBG001S81551
- Ticker Root
- DCTH
- SIC Code
- 3841
About Delcath Systems Inc (DCTH) Stock
Delcath Systems Inc (DCTH) closed the 2026-09-17 session at $16.25, up 0.18% versus the previous close (+0.03). The stock opened at $16.47 and traded between $16.12 and $16.50 during that session. Session trading volume was 437K shares. The volume-weighted average price (VWAP) is $16.28.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Delcath Systems Inc has a market capitalization of $562.8 million. The company operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry classification. DCTH is listed on the XNAS exchange. The company employs approximately 156 people. Delcath Systems Inc is headquartered in QUEENSBURY, NY. The recorded listing date is 2000-10-19.
On this page you can find market DCTH stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector.